Safety study of an experimental asthma medicine
Treatments studied
Part of Immune system & allergy, Lungs & breathing clinical trials.
This study tests an experimental medicine (PF-08103402) to see how well it is tolerated and how it acts in the body, in healthy adults and in people with mild-to-moderate asthma. Participation may help researchers learn if this treatment could help manage asthma symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You are male or female and are unable to have children (for example, due to surgery or menopause).
- Your body weight is over 110 pounds (50 kg), and your body mass index is within a certain range (16-32 for healthy participants, 16-35 for those with asthma).
- For people with asthma: you must have a doctor's diagnosis of asthma for at least 12 months, and you must not have had an asthma attack in the last 3 months.
- You do not have any significant medical conditions, HIV, hepatitis B or C, or a history of alcohol or drug abuse.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational medicine called PF-07275315 for people with moderate-to-severe asthma that is not well controlled with current treatments. The goal is to see if it can reduce asthma attacks and improve breathing.
This study tests an investigational drug (called JNJ-95597528) taken as a pill, to see if it can reduce asthma attacks and improve control in people with moderate to severe asthma that isn't well controlled by current inhalers. It may be a new option to help reduce airway inflammation and improve your breathing.
This study tests a new medicine called tozorakimab for adults whose asthma is not well controlled despite using their usual inhalers. It aims to see if it can reduce asthma attacks and improve symptoms.
This study tests an experimental drug called 610 for people with severe asthma that is not well-controlled with standard medicines. The goal is to see if adding 610 can improve asthma control and reduce flare-ups.
This early-phase study tests an inhaled medication (CHF10136) to see if it's safe and how the body handles it. It includes both healthy adults and people with asthma, and participants will be monitored closely throughout.
This Phase 2 study tests anti-inflammatory lipid mediators in people with asthma. You may be eligible if your asthma is not well controlled despite regular inhaler use and you meet the specific lung function and health criteria.
Hear when a new Asthma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.